$3.8B. The largest deal this field has seen.

THE DISPATCH

On July 20, 2026, Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion, the largest deal the psychedelic medicine sector has recorded.¹ It follows AbbVie's acquisition of Gilgamesh Pharmaceuticals' lead program eleven months earlier.³ Two of the largest pharmaceutical companies in the world have now made billion-dollar bets on psychedelic-class compounds within the same year. This is not a fringe conversation anymore. The institutions, the capital, and the clinical data are converging.

In this issue:

→ What the Lilly-AtaiBeckley deal actually buys, and what it does and doesn't tell us about the field's maturity

→ What happened to the programs and people left behind when AbbVie's deal took only part of a company's pipeline

→ A federal research signal on ibogaine, a new Phase 1 trial to watch, and a look at how concentrated this capital really is

---

THE SCIENCE

On July 20, 2026, Eli Lilly announced it will acquire AtaiBeckley in a deal structured as $6.75 per share in cash at closing, an equity value of roughly $2.8 billion, plus contingent value rights of up to $2.50 per share tied to clinical, regulatory, and commercialization milestones, bringing the deal's potential total value to $3.8 billion.¹ ² The acquisition centers on BPL-003 (mebufotenin benzoate), a synthetic 5-MeO-DMT nasal spray in Phase 3 development for treatment-resistant depression, along with VLS-01, a DMT buccal film, and EMP-01, an R-MDMA candidate for social anxiety, both in Phase 2.² The transaction is expected to close in the third quarter of 2026, subject to shareholder and regulatory approval.

Worth noting precisely what AtaiBeckley's pipeline actually is: 5-MeO-DMT, DMT, and MDMA-class compounds, not psilocybin. The reason this still reads as a psychedelic medicine story, rather than simply an Eli Lilly pipeline story, is the pattern it completes. Eleven months earlier, in August 2025, AbbVie agreed to acquire Gilgamesh Pharmaceuticals' lead candidate, bretisilocin, a synthetic short-acting 5-HT2A receptor agonist and 5-HT releaser then in Phase 2 for major depressive disorder, in a deal worth up to $1.2 billion.³ Two of the largest pharmaceutical companies in the world have now made billion-dollar bets on this compound class within less than a year of each other, a signal of institutional risk appetite for the therapeutic category as a whole, not just confidence in a single company's asset.

For readers tracking the psilocybin-specific side of this field, primarily Compass Pathways' synthetic psilocybin (COMP360) program, this deal doesn't translate into direct evidence about psilocybin's own regulatory or reimbursement path. What it does indicate is that the infrastructure problem we've tracked here for months, billing codes, payer readiness, provider training for supervised-session psychedelic therapies, is now a problem multiple deep-pocketed companies are motivated to help solve, since Lilly and AbbVie need that same infrastructure in place for their own newly acquired assets.

The acquisition also shows what happens to a research program when only part of a company's pipeline gets bought. Gilgamesh Pharmaceuticals didn't disappear once AbbVie took bretisilocin. The remaining team and unacquired programs spun out as Gilgamesh Pharma and closed an oversubscribed $60 million Series A in March 2026, funded in part by capital retained from the AbbVie deal.⁴ One of that company's remaining assets, GM-3009, a cardio-safe ibogaine analog, is on track to enter Phase 1 trials later this year.⁴ Acquisitions like this tend to reallocate capital toward the assets closest to market rather than shrink the overall pipeline, freeing everything else to raise independently instead of disappearing.

Whether that capital eventually reaches the psilocybin-specific therapies and infrastructure this newsletter tracks most closely is the open question worth watching through the rest of 2026.

---

THE STORY

When AbbVie agreed to acquire bretisilocin from Gilgamesh Pharmaceuticals in August 2025, the story easily could have ended there for the rest of the company's pipeline.³ It didn't. The scientists and programs AbbVie didn't acquire regrouped as Gilgamesh Pharma, retained a portfolio of unacquired neuropsychiatric compounds, and by March 2026 had closed a $60 million Series A, oversubscribed, to keep developing them.⁴ GM-3009, a cardio-safe ibogaine analog inherited from the original pipeline, is on track for Phase 1 trials later this year.⁴ Eli Lilly's acquisition of AtaiBeckley eleven months later is the bigger deal by dollar figure, but the more instructive story sits inside the smaller one. Capital leaving a psychedelic biotech through acquisition doesn't have to mean the science stops. More often, it means the part that wasn't bought has to find its own way forward, and increasingly, it does.

Rose Hill Life Sciences is a psychedelic research organization – specializing in the production and research of Psilocybe cubensis operating at the intersection of science and therapeutic integration.

---

ON OUR RADAR

① Executive Order on Ibogaine Research: What It Signals for the Broader Field On April 18, 2026, President Trump signed an executive order expanding federal research into ibogaine, the strongest federal endorsement of psychedelic medicine research to date for any compound in this class.⁵ Psychedelic company stocks moved on the announcement. The order is specific to ibogaine, not psilocybin, and does not change psilocybin's own scheduling or research pathway. Its significance here is indirect: it signals that federal openness to funding psychedelic-adjacent research is broadening beyond the compounds already furthest along in trials.⁵

② GM-3009 Heads to Phase 1 Gilgamesh Pharma's cardio-safe ibogaine analog, GM-3009, is expected to enter Phase 1 trials later in 2026, the first concrete clinical readout from the company's post-AbbVie pipeline.⁴ Worth tracking as an early signal of whether the executive order above translates into faster trial starts, not just capital formation.

③ A Caution on Reading the Hype Capital in this sector is concentrating around late-stage, proven assets rather than spreading evenly across the field. Compass Pathways itself raised roughly $350 million this year between a public offering and warrant exercises following its second Phase 3 readout, and analysts note that 2026's funding environment increasingly favors mid-to-late-stage programs over early-stage speculation.⁶ Two billion-dollar acquisitions make for a strong headline, but most of the money in this space is still going to a small number of assets closest to market.⁶

---

YOU ASKED

Q: "As an investor, how should I read Big Pharma's growing involvement here, dilution risk to smaller psychedelic biotechs, or validation for the field?"

Both, and they're not in conflict. Lilly and AbbVie paying billions for psychedelic-class assets is real validation. Companies that size don't make acquisitions like this speculatively, they make them because their own diligence supports the underlying science and market opportunity. That validation does concentrate value in the specific assets acquired, and it can make it harder for smaller, earlier-stage companies to raise on comparable terms. But it also builds the infrastructure, regulatory relationships, and payer familiarity that earlier-stage companies, including ones working specifically on psilocybin, will eventually need. Read these deals as evidence the category is maturing, not as a signal the opportunity has already been captured.

---

This week's takeaway: two of the largest pharmaceutical companies in the world have made billion-dollar bets on psychedelic-class compounds within eleven months of each other. That's evidence the category is maturing, even though neither deal involves psilocybin directly.

A question worth sitting with: if capital is now flowing this readily into psychedelic-adjacent pipelines, what does that mean for how quickly the billing and reimbursement infrastructure gets built, and who ends up building it?

Read the full deal terms directly: Forbes — Big Pharma and Psychedelic Medicine: Eli Lilly's $3.8 Billion Bet

If someone in your network is building thesis in psychedelic medicine and not yet reading The Rose Hill Review, forward this. The field is moving faster than most people realize.

— Domenic Suppa

Founder and COO, Rose Hill Life Sciences

Advancing the development of novel psychedelic-based therapeutics

---

FOOTNOTES

¹ Forbes. "Big Pharma And Psychedelic Medicine—Eli Lilly's $3.8 Billion Bet." July 20, 2026. https://www.forbes.com/sites/robertglatter/2026/07/20/big-pharma-and-psychedelic-medicine-eli-lillys-38-billion-bet/

² Yahoo Finance / Proactive Investors. "AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion." July 2026. https://finance.yahoo.com/healthcare/articles/ataibeckley-acquired-lilly-deal-valued-124100499.html

³ AbbVie. "AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline." August 25, 2025. https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline

⁴ BioSpace. "Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies." March 24, 2026. https://www.biospace.com/press-releases/gilgamesh-pharma-closes-oversubscribed-60-million-series-a-to-develop-next-generation-neuropsychiatric-therapies

⁵ Investing News Network. "Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain." 2026. https://investingnews.com/executive-order-boosts-psychedelics-biotech/

⁶ The Motley Fool. "5 Best Psychedelic Stocks for 2026 and How to Invest." 2026. https://www.fool.com/investing/stock-market/market-sectors/healthcare/psychedelic-stocks/

---

The Rose Hill Review